The Neuroscience of Parkinson's Disease
- 1st Edition - September 23, 2020
- Latest edition
- Editors: Colin R. Martin, Victor R. Preedy
- Language: English
The Neuroscience of Parkinson’s Disease (two volume set) provides a single source of material covering different scientific domains of neuropathology underlying this condit… Read more
The Neuroscience of Parkinson’s Disease (two volume set) provides a single source of material covering different scientific domains of neuropathology underlying this condition. The book covers a wide range of subjects and unravels the complex relationships between genetics, molecular biology, pharmaceutical chemistry, neurobiology, imaging, assessments, and treatment regimens. The book also fills a much-needed gap as a "one-stop" synopsis of everything to do with the neurology and neuroscience related to Parkinson’s disease—from chemicals and cells to individuals. It is an invaluable resource for neuroscientists, neurologists, and anyone in the field.
- Offers the most comprehensive coverage of a broad range of topics related to Parkinson's disease
- Serves as a foundational collection for neuroscientists and neurologists on the biology of disease and brain dysfunction
- Contains in each chapter an abstract, key facts, mini dictionary of terms, and summary points to aid in understanding
- Features preclinical and clinical studies to help researchers map out key areas for research and further clinical recommendations
- Serves as a "one-stop" source for everything you need to know about Parkinson’s disease
Neuroscientists/neurologists, psychologists, health scientists, public health workers, research scientists, pharmacologists, and physicians. Graduate/postgraduate students, lecturers, and professors
DIAGNOSIS AND MANAGEMENT IN PARKINSON'S DISEASE
Foreword
Virginia Bottomley
Preface
I. Introductory Chapters and Setting the Scene
1. Progression of symptoms in Parkinson's disease
Lucilla Parnetti
2. Cellular pathophysiology and basal ganglia dysfunction in Parkinson's disease: An Overview
Heinz Reichmann and Kai Felix Loewenbrueck
3. The role of environmental toxins and inflammation in Parkinson’s disease pathophysiology: a historical perspective and research-based evidence
Heinz Reichmann and Kai Felix Loewenbrueck
4. Risk factors in Parkinson's Disease: genetic and nongenetic
Evangelos Evangelou
5. Recent developments in the etiology, treatment and potential therapeutic targets for Parkinson's Disease: a focus on biochemistry
Athanasios Alexiou
6. Facial emotions and Parkinson's disease
G. Di Gennaro and Marco De Risi
7. The role of the circadian system in Parkinson’s Disease
G. Willis
8. Parkinson's disease and social media
Ibrahim S. Al-Busaidi
9. Sleep in Parkinson's disease
Marcelo M. S. Lima
10. Recurrent falls in Parkinson's disease
Lorena Rosa Santos de Almeida
11. Parkinsons patients deciding their own treatment
J. Koerts
12. Visual impairment in Parkinson's disease
Alessandro Arrigo
13. Autonomic problems in Parkinson’s disease: a focus on the bladder
Ryuji Sakakibara
14. Autonomic problems in Parkinson’s disease: a focus on the bowel
Ryuji Sakakibara
15. Linking and comparing nonmotor symptoms in ageing and Parkinson’s disease
Petra Bago Rozankovic
16. Progression of motor symptoms in Parkinson's Disease
Joana Ribeiro and Daniela Vieira
17. The stigma of Parkinson's disease
Benjamin K.P. Woo
II. Biomarkers, Instruments, Diagnosis and Assessments
18. Better neuroradiological approaches for the diagnosis of early stage Parkinson's disease patients
Tatsuro Mutoh
19. Use of positron emission tomography (PET) as a diagnostic and differential diagnostic tool in Parkinsonian syndromes
Maja Trost
20. Finger typing for the detection of early Parkinson's Disease
Warwick Adams
21. CSF biomarkers of Parkinson's disease
P. Lewitt
22. Application of eye movement tasks as an aid to understanding Parkinson's disease pathophysiology
Kikuro Fukushima
23. Measuring quality of life
Pablo Martinez Martin and Camen Rodriquez-Blazquez
24. Clinically assessing cognitive function in Parkinson’s disease
Ryan Anderton
III. Pharmacological Treatments, Other Agents and Strategies
25. Good news for the drug therapy of Parkinson`s disease
L. Bergantin
26. Dopamine Agonists and Parkinson’s disease: an overview
Aloke K. Dutta
27. Management with apomorphine in Parkinson’s disease
Manon Auffret
28. Management with MAO-B Inhibitors in Parkinson’s disease
T. Mueller
29. Management with antibiotics in Parkinson’s disease
Elaine Del-Bel and Mariza Bortolanza
30. Administration of dopamine in the brain in Parkinson’s disease
David Devos
31. Placebo and nocebo effects in Parkinson's disease
Fabrizio Benedetti
32. Levodopa-induced dyskinesias
N. S. Narayanan and Stephanie Alberico
33. Cannabinoid receptor type 2 as a therapeutic target for Parkinson’s disease
Miguel Abellanas and M. Aymerich
IV. Non-Pharmacological, Novel and Other Treatment Procedures
34. Deep Brain Stimulation Surgery in Parkinson's Disease
Hesham Abboud
35. Gene delivery for Parkinson’s disease
M. Airavaara and Andrii Domanskyi
36. Transdifferentiation of glial cells into dopamine neutrons via viral vectors/ Introducing transgenes into cells into the brain
M. Airavaara and Andrii Domanskyi
37. Urso- and tauroursodeoxycholic acids as anti-apoptotic agents: Modulation of Parkinson's disease
Noha Abdelkader
38. Interlinking potential therapy with botulinum neurotoxin A and Parkinson's disease
Andreas Wree
39. Neuropeptide CART (cocaine-amphetamine-regulated transcript) and usage in Parkinson's disease
P. Mao
40. Photobiomodulation as a neuroprotective strategy for Parkinson’s disease
Daniel M. Johnstone
41. Assisted devices in Parkinson's disease
Roongroj Bhidayasiri
GENETICS, NEUROLOGY, BEHAVIOR, AND DIET IN PARKINSON'S DISEASE
Foreword
Virginia Bottomley
Preface
I. Genetics, Molecular and Cellular Biology
1. LRRK2 genes in Parkinson’s disease: from genetics to pathobiology
Elisa Greggio and Susanna Cogo
2. Alpha-synuclein gene and Parkinson’s disease
Leonidas Stefanis
3. The DJ-1 gene and protein: links with Parkinson's Disease
Paul R. Fisher
4. Gene expression in the connection between 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and tyrosine hydroxylase
Gelareh Alam and Jason Richardson
5. Linking GBA variants and Parkinson's disease
Mathias Toft
6. Astrocytes and microglia in Parkinson’s disease and its animal models
Katarzyna Z. Kuter
7. Autophagy in Parkinson’s disease
Sandra Morais Cardoso and Nilza Manadas
8. Mitochondria in Parkinson’s disease
Sabrina Buettner
9. Signal transduction in Parkinson's disease
Mattia Volta
10. Oxidative stress signaling and regulated cell death in Parkinson’s disease
Marlene Jimenez-Del-Rio and Carlos Velez-Pardo
11. Subcellular-specific alpha-synuclein in Parkinson's Disease
Simon Geir Moller and Benjamin Rosen
12. MC1R in Parkinson's disease and association with melanoma risk
Susana Puig and Gemma Tell-Marti
13. Energy regulation and Parkison's disease
Kah-Leong Lim
14. Linking rotigotine, Parkinsons disease and brain BDNF
H. Kunugi
II. Neurology, Physiology and Imaging
15. The different syndromes in Parkinson’s disease: an overview
Maria Stamelou and Nikolaos Giagkou
16. Neuromolecular imaging in Parkinson’s disease
P. Broderick
17. Interlinking brain mapping and Parkinson's disease: MRI analysis, nigrosome 1 and nigrosome 4
Eung Yeop Kim
18. Interconnecting Parkinson’s disease, computed tomography (CT) and microelectrode recording in deep brain stimulation
Sepehr Sani and Ryan B. Kochanski
19. Linking diffusion tensor imaging (DTI), microstructures and Parkinson’s disease
Yu Zhang
20. Hypointensity in the substantia nigra pars compacta in Parkinson’s disease
Xiaoping Hu and Jason Langley
21. Vagal motoneurons in Parkinson’s disease
Joshua A. Goldberg and Ruth Musgrove
22. Circadian clock disruption and neuroinflammation in Parkinson’s disease: a new perspective
Elisabetta Lauretti and Domenico Pratico
23. Motor cortex stimulation in Parkinson’s disease
A. Lavano
24. Action programming disorders associated with Parkinson's Disease
Kenneth M. Heilman
25. The striatal medium spiny neurons (MSNs): what they are and how they link with Parkinson's disease
Fu-Ming Zhou
26. Disruptions of frontostriatal language functions in Parkinson's Disease
Adolfo M. Garcia
27. Synuclein and neuroinflammation in Parkinson's disease
Luigi Bubacco
28. Tau and its interactions with other proteins in neurodegenerative disease
Paul R. Fisher
29. Dopamine and the renin-angiotensin system in neuronal tissues Parkinson's Disease
Jose Luis Labandeira Garcia
30. Restoring dopamine levels in Parkinson’s disease
Henning Ulrich and Ágatha Oliveira-Giacomelli
III. Behaviour and Psychopathology
31. Motivation and motivational aspects of Parkinson's disease
Abdeslam Chagraoui
32. Linking anxiety, cognitive and sensory deficits to gait and balance in Parkinson’s disease
Quincy J. Almeida
33. Interlinking motor program of gait and bradykinesia in Parkinson's disease
Tateo Warabi
34. Olfactory features in Parkinson's disease
Marcelo M. S. Lima
IV. Diet And Nutrition
35. Interlinking dementia in Parkinson's disease: and nutritional correlates of body composition
Arthur Oscar Schelp
36. The role of the gut microbiota in Parkinson's disease
Ryan Anderton and Jade Kenna
37. Swallowing defects in Parkinson’s disease
Maira Rozenfeld Olchik
38. The Mini Nutritional Assessment (MNA ) and applications to Parkinson’s disease
Svetlana Tomic
39. Bacopa monnieri extract and Parkinson’s disease
Ravikumar Hosamani
V. Models, Modelling and Resources
40. 6-hydroxydopamine-induced model of Parkinson’s disease
Katarzyna Kaczynska
41. Knockdown transgenic Drosophila and Parkinson’s disease
Carlos Velez-Pardo and Marlene Jimenez-Del-Rio
42. Evidence for neuroprotection in animal models of Parkinson’s disease
John Mitrofanis
43. Modelling with the A53T alpha-synuclein model of Parkinson’s disease
CW Ip
44. Linking the leucine-rich repeat kinase 2 (LRRK2) gene, animals models and Parkinson’s disease
Yulan Xiong
Resources
Rajkumar Rajendram
- Edition: 1
- Latest edition
- Published: September 23, 2020
- Language: English
CM
Colin R. Martin
Colin R. Martin RN, BSc, MSc, PhD, MBA, YCAP, FHEA, C.Psychol, AFBPsS, C.Sci is Professor of Clinical Psychobiology and Applied Psychoneuroimmunology and Clinical Director of the Institute of Health and Wellbeing at the University of Suffolk, UK. He is a Chartered Health Psychologist and a Chartered Scientist. He also trained in analytical biochemistry, this aspect reflecting the psychobiological focus of much of his research within mental health. He has published or has in press well over 300 research papers and book chapters. He is a keen book author and editor having written and/or edited more than 50 books. These outputs include the prophetic insight into the treatment of neurological disease, Handbook of Behavior, Food and Nutrition (2011), Nanomedicine and the Nervous System (2012), Oxidative Stress and Dietary Antioxidants in Neurological Disease (2020), Zika Virus Impact, Diagnosis, Control and Models (2021), Factors Affecting Neurodevelopment: Genetics, Neurology, Behavior and Diet (2021), Diagnosis and Treatment of Spinal Cord Injury (2022), The Neurobiology, Physiology, and Psychology of Pain (2022) and The Handbook of Lifespan Cognitive Behavioral Therapy: Childhood, Adolescence, Pregnancy, Adulthood, and Aging (2023). Professor Martin is particularly interested in all aspects of the relationship between underlying physiological substrates and behavior, particularly in how these relationships manifest in both acute and chronic psychiatric disorder. He has published original research germane to significant mental health disorders including the areas of schizophrenia, anxiety, depression, self-esteem, alcohol and drug dependency, high secure forensic mental health and personality disorder. He has a keen interest in the impact of postviral illness and is actively involved in clinical research post-Covid pandemic and in particular, the impact of Long Covid on psychological, neurological, physiological and social functioning. He is involved in collaborative International research with many European and Non-European countries.
Affiliations and expertise
Visiting Professor of Perinatal Wellbeing, Institute for Health and Wellbeing, University of Suffolk, Ipswich, UKVP
Victor R. Preedy
Victor R. Preedy BSc, PhD, DSc, FRSB, FRSPH, FRSC, FRCPath graduated with an Honours Degree in Biology and Physiology with Pharmacology. After gaining his University of London PhD, he received his Membership of the Royal College of Pathologists. He was later awarded his second doctorate (DSc), for his contribution to protein metabolism in health and disease. He is Professor of Clinical Biochemistry (Hon) at King’s College Hospital and Emeritus Professor of Nutritional Biochemistry at King’s College London. He has Honorary Professorships at the University of Hull, and the University of Suffolk. Professor Preedy was the Founding Director and then long-term Director of the Genomics Centre at King’s College London from 2006 to 2020. Professor Preedy has been awarded fellowships of the Royal Society of Biology, the Royal College of Pathologists, the Royal Society for the Promotion of Health, the Royal Institute of Public Health, the Royal Society for Public Health, the Royal Society of Chemistry and the Royal Society of Medicine. He carried out research when attached to the National Heart Hospital (part of Imperial College London), The School of Pharmacy (now part of University College London) and the MRC Centre at Northwick Park Hospital. He has collaborated with international research groups in Finland, Japan, Australia, USA, and Germany. To his credit, Professor Preedy has published over 750 articles, which includes peer-reviewed manuscripts based on original research, abstracts and symposium presentations, reviews and edited books.
Affiliations and expertise
Professor, Department of Clinical Biochemistry, King’s College Hospital, London, UK; Emeritus Professor, Faculty of Life Sciences and Medicine, King’s College London, UK; Visiting Professor, University of Hull, UK